VivoSeq
Metabolic & Endocrine

Aicardi-Goutières Syndrome

7

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Aicardi-Goutières syndrome is an early-stage landscape with 7 programs across 5 companies. The most active players are Transposon Therapeutics, Inc., Glaxo Dba Glaxosmithkline, GSK. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Transposon Therapeutics, Inc.

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2GSK logo

GSK

2 programs

Phase 2Gilead logo

Gilead

1 program

ApprovedEli Lilly logo

Eli Lilly

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome
Completed·UUniversity of Edinburgh·Phase 2·NCT04731103·13 enrolled
Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome
Completed·IIRCCS Fondazione Stella Maris·N/A·NCT06898372·24 enrolled
TPN-101 in Aicardi-Goutières Syndrome (AGS)
Active, not recruiting·TTransposon Therapeutics, Inc.·Phase 2·NCT05613868·16 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)